Enduro Genetics Raises €12M to Transform the Efficiency of Biomanufacturing at Scale
Danish biotech company Enduro Genetics has secured €12 million in Series A funding for a new patented “synthetic addiction” technology with the potential to slash costs and emissions in biomanufacturing. The biomanufacturing industry — encompassing alternative proteins, industrial enzymes, biodegradable materials, and pharmaceuticals — is plagued by declining productivity at the industrial scale. This happens because large-scale processes cause microorganisms to mutate, creating cell-to-cell variation as cells prioritize their survival over production. Eventually, the non-productive cells outcompete the productive ones for space and nutrients, causing a drop-off in yields. Enduro’s “synthetic addiction” technology addresses this by integrating a genetic plug-in into the microbial production host. This couples the productivity of each cell to its health and growth, meaning only high-producing cells can survive. The technology …
